Concentra Group Holdings Parent Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw double-digit revenue and EBITDA growth, driven by strong workers' compensation volumes, successful acquisition integrations, and improved margins. Guidance for 2026 was raised across revenue, EBITDA, and Free Cash Flow, with continued focus on expansion and operational efficiency.
-
The company reinforced its leadership in occupational health, reporting strong revenue and EBITDA growth, high patient satisfaction, and successful integration of recent acquisitions. Strategic focus remains on organic growth, disciplined M&A, and flexible capital allocation, with positive rate and volume trends expected to continue.
Fiscal Year 2025
-
Revenue and Adjusted EBITDA exceeded guidance in 2025, driven by strong organic growth, successful acquisitions, and cost efficiencies. 2026 guidance projects continued growth, margin stability, and robust capital deployment, with a focus on de novos and small M&A.
-
Q3 2025 saw 17% revenue growth and strong adjusted EBITDA, driven by organic and acquisition-fueled expansion. Guidance for 2025 was raised, with continued focus on deleveraging, technology investment, and disciplined M&A. No major headwinds are anticipated for 2026.
-
Q2 2025 saw strong revenue and visit growth, successful integration of major acquisitions, and raised full-year guidance. Margins were slightly lower due to one-time costs, but cash flow and deleveraging remain on track. No major reimbursement or labor risks identified.
-
The group maintains a leading position in occupational health, with diversified revenue from workers' comp and employer services. Growth is driven by steady visit volumes, inflation-linked pricing, and expansion through acquisitions and new service offerings. Leverage is targeted to decline as integration and cash flow improve.
-
Q1 2025 saw strong revenue and visit growth, margin stability, and major acquisitions, with both core and acquired businesses contributing. Guidance for 2025 was raised, reflecting robust performance and integration of new centers, while the company remains vigilant on macro risks.
-
Preliminary 2024 results exceeded expectations, with strong revenue and EBITDA growth. The Nova Medical Centers acquisition will expand the footprint, especially in Texas, and is expected to be immediately accretive. 2025 guidance projects double-digit revenue and EBITDA growth.
Fiscal Year 2024
-
Q4 2024 saw 5.5% revenue growth and margin expansion, with strong cash flow and a major acquisition of Nova Medical Centers. 2025 guidance projects double-digit revenue and EBITDA growth, with improving labor market trends and continued expansion, especially in Florida.
-
Q3 2024 saw 3.3% revenue growth and 2.7% adjusted EBITDA growth, with strong cash flow and margin stability despite a slight decline in total visits. Guidance for 2024 remains robust, supported by higher reimbursement rates and ongoing expansion, while employer services volumes remain sensitive to labor market trends.
-
Q2 2024 saw 2.3% revenue growth and a successful IPO, with net income slightly down and EBITDA margin stable. Workers' compensation visits and revenue per visit increased, while employer services visits declined. Growth is expected to accelerate in Florida due to new reimbursement laws.